EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Chemoresistance in gliomas accounts for the major cause of tumor progress and recurrence during comprehensive treatment with alkylating agents including temozolomide (TMZ). The oncogenic role of Enhancer of zeste homolog 2 (EZH2) has been identified in many solid malignancies including gliomas, though the accurate effect of EZH2 on chemotherapy resistance of gliomas has been elusive.
OBJECTIVE: To elucidate the role of EHZ2 on TMZ resistance of gliomas and the molecular mechanisms.
METHODS: Immunohistochemistry (IHC) and Reverse transcription-quantitative (RT-q) PCR, and western blot assay were performed for expressional analysis. Cell Counting Kit-8 (CCK-8) assay was applied to determine the TMZ sensitivity. EZH2-silencing lentivirus was generated for mechanic study.
RESULTS: EZH2 was overexpressed in gliomas both at the transcriptional and protein levels. EZH2 level in glioma cell lines was positively correlated with resistance to TMZ, represented by the 50% inhibition rate (IC50). Moreover, there was increased TMZ sensitivity in EZH2-inhibited glioma cells than in the control cells. Furthermore, we determined that PARP1 was a common molecule among the downregulated DNA repair proteins in both U251 and U87 glioma cell lines after EZH2 inhibition. Specifically, we observed a spontaneous increase of PARP1 expression with TMZ treatment and interestingly, the increase of PARP1 could be also reduced by EZH2 inhibition in the glioma cells. Finally, combined treatment with lentivirus-induced EZH2 inhibition and a PARP1 inhibitor dramatically enhanced TMZ cytotoxicity compared with either one alone.
CONCLUSION: EZH2-PARP-1 signaling axis is possibly responsible for the chemoresistance of gliomas to TMZ. Simultaneously inhibiting these two genes may improve the outcome of TMZ chemotherapy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Current cancer drug targets - 24(2024), 3 vom: 01., Seite 328-339 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Liang, Qiang [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 05.04.2024 Date Revised 05.04.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1568009623666230818151830 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM360930190 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM360930190 | ||
003 | DE-627 | ||
005 | 20240405233105.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1568009623666230818151830 |2 doi | |
028 | 5 | 2 | |a pubmed24n1366.xml |
035 | |a (DE-627)NLM360930190 | ||
035 | |a (NLM)37594167 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Liang, Qiang |e verfasserin |4 aut | |
245 | 1 | 0 | |a EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 05.04.2024 | ||
500 | |a Date Revised 05.04.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a BACKGROUND: Chemoresistance in gliomas accounts for the major cause of tumor progress and recurrence during comprehensive treatment with alkylating agents including temozolomide (TMZ). The oncogenic role of Enhancer of zeste homolog 2 (EZH2) has been identified in many solid malignancies including gliomas, though the accurate effect of EZH2 on chemotherapy resistance of gliomas has been elusive | ||
520 | |a OBJECTIVE: To elucidate the role of EHZ2 on TMZ resistance of gliomas and the molecular mechanisms | ||
520 | |a METHODS: Immunohistochemistry (IHC) and Reverse transcription-quantitative (RT-q) PCR, and western blot assay were performed for expressional analysis. Cell Counting Kit-8 (CCK-8) assay was applied to determine the TMZ sensitivity. EZH2-silencing lentivirus was generated for mechanic study | ||
520 | |a RESULTS: EZH2 was overexpressed in gliomas both at the transcriptional and protein levels. EZH2 level in glioma cell lines was positively correlated with resistance to TMZ, represented by the 50% inhibition rate (IC50). Moreover, there was increased TMZ sensitivity in EZH2-inhibited glioma cells than in the control cells. Furthermore, we determined that PARP1 was a common molecule among the downregulated DNA repair proteins in both U251 and U87 glioma cell lines after EZH2 inhibition. Specifically, we observed a spontaneous increase of PARP1 expression with TMZ treatment and interestingly, the increase of PARP1 could be also reduced by EZH2 inhibition in the glioma cells. Finally, combined treatment with lentivirus-induced EZH2 inhibition and a PARP1 inhibitor dramatically enhanced TMZ cytotoxicity compared with either one alone | ||
520 | |a CONCLUSION: EZH2-PARP-1 signaling axis is possibly responsible for the chemoresistance of gliomas to TMZ. Simultaneously inhibiting these two genes may improve the outcome of TMZ chemotherapy | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a DNA repair | |
650 | 4 | |a EZH2 | |
650 | 4 | |a PARP1. | |
650 | 4 | |a chemoresistance | |
650 | 4 | |a glioma | |
650 | 4 | |a temozolomide | |
650 | 7 | |a Temozolomide |2 NLM | |
650 | 7 | |a YF1K15M17Y |2 NLM | |
650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
650 | 7 | |a Dacarbazine |2 NLM | |
650 | 7 | |a 7GR28W0FJI |2 NLM | |
650 | 7 | |a Antineoplastic Agents, Alkylating |2 NLM | |
650 | 7 | |a Enhancer of Zeste Homolog 2 Protein |2 NLM | |
650 | 7 | |a EC 2.1.1.43 |2 NLM | |
650 | 7 | |a EZH2 protein, human |2 NLM | |
650 | 7 | |a EC 2.1.1.43 |2 NLM | |
700 | 1 | |a Wang, Bing |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Chenran |e verfasserin |4 aut | |
700 | 1 | |a Song, Chaoli |e verfasserin |4 aut | |
700 | 1 | |a Wang, Junyu |e verfasserin |4 aut | |
700 | 1 | |a Sun, Wei |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Lei |e verfasserin |4 aut | |
700 | 1 | |a Lin, Jing |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d 2001 |g 24(2024), 3 vom: 01., Seite 328-339 |w (DE-627)NLM120490560 |x 1873-5576 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2024 |g number:3 |g day:01 |g pages:328-339 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1568009623666230818151830 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2024 |e 3 |b 01 |h 328-339 |